Stocks › TAK

TAKEDA PHARMACEUTICAL CO LTD

TAK·NYSE·Japan Japan·USD
$21.77
+0.36 (+1.68%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
TAK
TAKEDA PHARMACEUTICAL CO LTD · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
TAKS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of TAK by members of U.S. Congress · 21 on record · 3 in the last 12 months
All congressional trades →
PoliticianStockTypeFiledTraded
Ro KhannaRo KhannaHouse · D · CA TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Purchase
$1,001 - $15,000
Nov 5, 2026 Oct 9, 2026 Filing ↗
Alan ArmstrongAlan ArmstrongSenate · R · OK TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Purchase
$1,001 - $15,000
Jul 21, 2026 Mar 30, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Sale
$1,001 - $15,000
Mar 9, 2026 Feb 13, 2026 Filing ↗
Ro KhannaRo KhannaHouse · D · CA TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Purchase
$1,001 - $15,000
Jul 9, 2025 Jun 13, 2025 Filing ↗
Ro KhannaRo KhannaHouse · D · CA TAKTAKEDA PHARMACEUTICAL CO LTD · Common Stock Sale
$1,001 - $15,000
Jun 10, 2025 May 9, 2025 Filing ↗
Ro KhannaRo KhannaHouse · D · CA TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Purchase
$1,001 - $15,000
Apr 10, 2025 Mar 14, 2025 Filing ↗
Ro KhannaRo KhannaHouse · D · CA TAKTAKEDA PHARMACEUTICAL CO LTD · Common Stock Purchase
$1,001 - $15,000
Jan 8, 2025 Dec 13, 2024 Filing ↗
Virginia FoxxVirginia FoxxHouse · R · NC TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Sale
$15,001 - $50,000
Sep 5, 2023 Aug 29, 2023 Filing ↗
Daniel S. GoldmanDaniel S. GoldmanHouse · D · NY TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Sale
$15,001 - $50,000
Aug 13, 2023 Jul 10, 2023 Filing ↗
Ro KhannaRo KhannaHouse · D · CA TAKTAKEDA PHARMACEUTICAL CO LTD · Common Stock Purchase
$1,001 - $15,000
Apr 7, 2023 Mar 10, 2023 Filing ↗
Daniel S. GoldmanDaniel S. GoldmanHouse · D · NY TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Purchase
$1,001 - $15,000
Mar 20, 2023 Feb 27, 2023 Filing ↗
Ro KhannaRo KhannaHouse · D · CA TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Purchase
$15,001 - $50,000
Mar 3, 2023 Feb 10, 2023 Filing ↗
Virginia FoxxVirginia FoxxHouse · R · NC TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Purchase
$1,001 - $15,000
Mar 3, 2023 Feb 16, 2023 Filing ↗
Virginia FoxxVirginia FoxxHouse · R · NC TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Purchase
$1,001 - $15,000
Dec 6, 2022 Nov 1, 2022 Filing ↗
David P. RoeDavid P. RoeHouse · R · TN TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Sale
$1,001 - $15,000
Feb 14, 2020 Jan 30, 2020 Filing ↗
Greg GianforteGreg GianforteHouse · R · MT TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Sale
$1,001 - $15,000
Oct 20, 2019 Sep 11, 2019 Filing ↗
Nicholas Van TaylorNicholas Van TaylorHouse · R · TX TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Sale
$15,001 - $50,000
Apr 15, 2019 Mar 25, 2019 Filing ↗
Charles J. "Chuck" FleischmannCharles J. "Chuck" FleischmannHouse · R · TN TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Sale
$1,001 - $15,000
Mar 15, 2019 Jan 28, 2019 Filing ↗
Greg GianforteGreg GianforteHouse · R · MT TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Purchase
$15,001 - $50,000
Jan 23, 2019 Dec 21, 2018 Filing ↗
David P. RoeDavid P. RoeHouse · R · TN TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Sale
$1,001 - $15,000
Nov 13, 2017 Oct 10, 2017 Filing ↗
David P. RoeDavid P. RoeHouse · R · TN TAKTAKEDA PHARMACEUTICAL CO LTD · Stock Sale
$1,001 - $15,000
Jun 13, 2017 May 26, 2017 Filing ↗

Whale Activity

Position changes in TAK reported for 2026-09-30 by 439 institutional filers
Increased: 171New: 56Held: 62Decreased: 82Closed: 39No prior filing: 29
  • Increased171
  • New56
  • Held62
  • Decreased82
  • Closed39
  • No prior filing29
FilerSharesValueChange
Capital Research Global Investors27.0M$490.3Mincreased
FMR LLC11.0M$199.6Mincreased
MORGAN STANLEY8.2M$149.8Mincreased
ADAGE CAPITAL PARTNERS GP, L.L.C.7.2M$131.0Mincreased
GOLDMAN SACHS GROUP INC5.5M$100.8Mincreased
BRANDES INVESTMENT PARTNERS, LP4.2M$77.1Mdecreased
BlackRock, Inc.3.9M$71.6Mincreased
D. E. Shaw & Co., Inc.3.1M$57.1Mincreased
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP3.0M$54.5Mdecreased
RENAISSANCE TECHNOLOGIES LLC2.3M$41.7Mdecreased
Qube Research & Technologies Ltd2.2M$39.2Mdecreased
JPMORGAN CHASE & CO2.0M$36.3Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by TAK insiders, by quarter · Form 4
-1.0M-500.0K0500.0K1.0M2025 Q1: 02025 Q12025 Q2: 02025 Q22025 Q3: 02025 Q32025 Q4: 02025 Q42026 Q1: 02026 Q12026 Q2: 02026 Q22026 Q3: -749.3K2026 Q32026 Q4: -102.2K2026 Q4

Recent Insider Transactions

57 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Platford Giles RichardPresident, IBU Sale −55.6K $20.90 $1.2M Nov 4, 2026 Form 4 ↗
Bitetti Teresa MariePresident, OBU Sale −46.6K $20.89 $974K Nov 2, 2026 Form 4 ↗
Duprey Lauren RusckowskiChief Transformation Officer Sale −34.5K $18.54 $640K Sep 14, 2026 Form 4 ↗
Plump Andrew StewartPresident, R&D · Director Sale −116.2K $18.49 $2.1M Sep 2, 2026 Form 4 ↗
Plump Andrew StewartPresident, R&D · Director Sale −19.7K $18.49 $363K Aug 19, 2026 Form 4 ↗
Greenway Nicola Deidre PetalChief Human Resources Officer Sale −13.0K $18.11 $235K Aug 18, 2026 Form 4 ↗
Shannon Elaine MaryPres., Global Supply & Quality Sale −20.4K $17.55 $357K Aug 11, 2026 Form 4 ↗
Farajallah Awny Samaan BotrosChief Medical Officer Sale −14.0K $17.10 $240K Aug 10, 2026 Form 4 ↗
Ibrahim Ramy Riad AhmedPresident, PDT BU Sale −7,277 $17.10 $124K Aug 10, 2026 Form 4 ↗
Pacheco Rhonda JanicePresident, U.S. Business Unit Sale −16.9K $17.10 $289K Aug 10, 2026 Form 4 ↗
Duprey Lauren RusckowskiChief Transformation Officer Sale −47.6K $17.10 $814K Aug 10, 2026 Form 4 ↗
Plump Andrew StewartPresident, R&D · Director Sale −165.4K $17.10 $2.8M Aug 10, 2026 Form 4 ↗
Pignagnoli Agosti MarcelloHead, Strat. & Port. Dev Sale −23.0K $17.10 $393K Aug 10, 2026 Form 4 ↗
Bitetti Teresa MariePresident, OBU Sale −50.0K $17.10 $855K Aug 10, 2026 Form 4 ↗
Shannon Elaine MaryPres., Global Supply & Quality Sale −3,978 $17.10 $68K Aug 10, 2026 Form 4 ↗
Ricci GabrieleChief Data & Tech. Officer Sale −25.1K $17.10 $429K Aug 10, 2026 Form 4 ↗
Greenway Nicola Deidre PetalChief Human Resources Officer Sale −6,774 $17.10 $116K Aug 10, 2026 Form 4 ↗
Kim Julie So-YoungPresident and CEO · Director Sale −89.1K $17.10 $1.5M Aug 10, 2026 Form 4 ↗
Platford Giles RichardPresident, IBU Sale −31.1K $17.10 $532K Aug 10, 2026 Form 4 ↗
Furney Natalie Anne MarieGlobal General Counsel Sale −30.9K $17.10 $528K Aug 10, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding TAK · SEC Form N-PORT
FundSharesValue% of fundAs of
American Mutual Fund18.2M$310.3M0.26%Jul 31, 2026
Capital Income Builder7.3M$125.5M0.10%Jul 31, 2026
First Trust Value Line Dividend Index Fund
First Trust Exchange-Traded Fund
2.0M$32.5M0.40%Jun 30, 2026
VanEck Pharmaceutical ETF
VanEck ETF Trust
1.5M$27.7M2.71%Sep 30, 2026
Steward Values Enhanced International Fund
Steward Funds Inc
711.9K$12.2M3.58%Jul 31, 2026
Avantis International Equity ETF
American Century ETF Trust
553.0K$9.9M0.05%Aug 31, 2026
Mercer Non-US Core Equity Fund
Mercer Funds
513.8K$9.3M0.20%Sep 30, 2026
Goldman Sachs Income Builder Fund
GOLDMAN SACHS TRUST
494.4K$8.5M0.30%Jul 31, 2026
ActivePassive International Equity ETF
Trust for Professional Managers
168.3K$3.0M0.26%Aug 31, 2026
Catalyst/MAP Global Equity Fund
MUTUAL FUND SERIES TRUST
169.0K$2.7M2.84%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list TAK's shares (CUSIP 874060205), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings

No 13D/13G beneficial-ownership filings on record.

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming takeda pharmaceuticals as client
$0$2.5M$5.0M$7.5M$10.0M2023 Q1: $1.7M2023 Q2: $1.5M2023 Q3: $1.6M2023 Q4: $750K20232024 Q1: $700K2024 Q2: $1.3M2024 Q3: $1.2M2024 Q4: $980K20242025 Q1: $730K2025 Q2: $3.3M2025 Q3: $1.6M2025 Q4: $840K20252026 Q1: $1.7M2026 Q2: $870K2026 Q3: $1.8M2026
  • AVENUE SOLUTIONSTAKEDA PHARMACEUTICALS AMERICA, INC. · 2026 Q3 · HCR$50K
    Filing ↗
  • FARRAGUT PARTNERS LLPTAKEDA PHARMACEUTICALS AMERICA INC · 2026 Q3 · HCR$50K
    Filing ↗
  • TAKEDA PHARMACEUTICALS AMERICA, INC.TAKEDA PHARMACEUTICALS AMERICA INC · 2026 Q3 · MMM, HCR, TAX, TRD$1.4M
    Filing ↗
  • TIBER CREEK GROUPTAKEDA PHARMACEUTICALS AMERICA, INC. · 2026 Q3 · MMM$50K
    Filing ↗
  • TODD STRATEGY GROUPTAKEDA PHARMACEUTICALS AMERICA, INC. · 2026 Q3 · HCR, MMM, TRD$50K
    Filing ↗

Government Contracts

Federal awards to takeda pharmaceuticals · USAspending
$1.5MAwarded · 17 contracts on record
  • Department of JusticeFY27 PHARMACY TAKEDA$371K
    Oct 1, 2026 · ↗
  • Department of Veterans AffairsGAMMAGARD LIQUID ERC - GLOBULIN,IMMUNE (IV) 10% INJ$25K
    Apr 27, 2026 · ↗
  • Department of Veterans AffairsGAMMAGARD$58K
    Oct 1, 2026 · ↗
  • Department of Veterans AffairsLANADELUMAB-FLYO 150MG/ML INJ, SYRINGE,2ML (TAKHZYRO)$193K
    May 20, 2024 · ↗
  • Department of Veterans AffairsTAKHZYRO 150 MG$38K
    Aug 27, 2026 · ↗
  • Department of Veterans AffairsTAKHZYRO 150 MG$0
    Aug 27, 2026 · ↗
  • Department of JusticeFY26 PHARMACEUTICALS TAKEDA APRIL-SEPTEMBER$551K
    Apr 1, 2026 · ↗
  • Department of Veterans AffairsLIVTENCITY 200 MG$19K
    Aug 28, 2026 · ↗

U.S. Patents

Recent USPTO applications naming TAKEDA PHARMACEUTICAL CO LTD

No USPTO patent applications found for TAKEDA PHARMACEUTICAL CO LTD.

Annual Financials

From TAK's 10-K filings · XBRL

SEC's XBRL figures for TAKEDA PHARMACEUTICAL CO LTD include no full-year results from a 10-K in US dollars, so there is no table to show. Companies based abroad usually report annually on Form 20-F instead.

Stock Splits

Every split and reverse split in the price history

No stock splits in TAK's price history.

Material Events (8-K)

Corporate events filed with the SEC

No 8-K filings on record.

About TAKEDA PHARMACEUTICAL CO LTD

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersTOKYO, Japan